Alvotech, a vertically integrated biotechnology company, focuses solely on the development and manufacture of biosimilar medicines for patients worldwide.
The company’s vertically integrated platform is designed to enable the company to execute the…
Analysis
Middle-of-the-road
Alvotech sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
Valuation data is not available for this company.
Growth is moderate; the safety picture is fragile. The company scores 2/20 on our value-creation score: not creating value. Analyst sentiment is cautious.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202654
36
2026
All-time high
54
Mar 2026
All-time low
36
Jun 2026
Average rank
45
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
97
—
—
—
Price/Earnings
17
—
—
—
Price/Book
80
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
75
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.